NCT04608201已完成3 期
Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- The unfavorable outcome on Day 14
研究概览
简要总结
The coronavirus disease (COVID-19) epidemic represents a major therapeutic challenge. The highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and the long duration of the disease have led to a massive influx of patients admitted in health services and intensive care units. To current knowledge, there is no treatment yet that that can prevent infection from SARS-COV-2 virus, nor the disease progression to a severe form.
Daily active smokers are rare among outpatients or hospitalized COVID-19 patients.
Several arguments suggest that nicotine could be responsible for this protective effect thank to the nicotinic acetylcholine receptor (nAChR).
Based on epidemiological data and experimental data from scientific literature, we hypothesize that nicotine could inhibit the penetration and spread of the virus and improve the management of COVID19 , particularly in hospitalized patients to prevent adverse outcomes (death, transfer to intensive care unit, care limitation, mechanical ventilation an high flow oxygen).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Patients hospitalized for less than 72 hours
- •Non-smoking and non-vaping patients (for former smokers or former vapers: abstinent for at least 12 months)
- •Documented diagnosis of COVID19
- •Lung disease suggestive of COVID-19 on chest scanner or need for oxygen therapy
- •Obtaining, informed and signed consent
- •Affiliated to a social security scheme or beneficiary of such a scheme (except AME)
排除标准
- •WHO 10-point Clinical Progression Scale score > 5 (patient on non-invasive or mechanical ventilation, patient in need of high-flow oxygen therapy)
- •Indication of transfer to intensive care unit (oxygen therapy> 8 L / min ; out or not carried out due to LATA)
- •Current treatment with nicotine replacement therapy, bupropion or varenicline in the last 30 days
- •Known addiction problem to alcohol or other substances
- •Contraindication for nicotine patches:
- •pregnant or breastfeeding woman
- •lack of effective contraception for women of childbearing age
- •Generalized skin pathologies that may interfere with the use of a transdermal patch
- •stroke or myocardial infarction or acute coronary syndrome for less than 3 months
- •allergy to nicotine or to one of the excipients of the transdermal patch
- •Uncontrolled high blood pressure
- •Unstable or worsening angina
- •Severe cardiac arrhythmia (defined by wearing an automatic implantable defibrillator)
- •Known obliterating peripheral arterial disease
- •Known severe heart failure with an ejection fraction <30%)
- •Known severe renal (ClCr <30 ml / min) or hepatic (Child C) impairment
- •Known pheochromocytoma
- •Known uncontrolled hyperthyroidism
- •Esophagitis due to gastroesophageal reflux disease or an active peptic ulcer
- •Patient included in another interventional trial evaluating a health product
- •Patient under guardianship or curatorship
- •Patient deprived of liberty by judicial or administrative decision
研究组 & 干预措施
NICOTINE transdermal patch
Experimental
NICOTINE 7 mg / 24h, transdermal patch
干预措施: Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour (Drug)
Placebo of NICOTINE transdermal patch
Placebo Comparator
Placebo of nicotine patch
干预措施: Placebo of NICOTINE Transdermal patch (Drug)
结局指标
主要结局
The unfavorable outcome on Day 14
时间窗: Day 14
Defined by scores higher than 5 on the World Health Organization 10-point Clinical Progression Scale (WHO-CPS) on day 14
次要结局
- Proportion of patient with a score higher than 6 on the World Health Organization 10-point Clinical Progression Scale(Day 14)
- Mean evolution of glycemia(At randomization then every 3 days until discharge, or up to 5 weeks)
- Mean score of Desire to smoke defined by French Tobacco Craving questionnaire (FTCQ12 )(Week 2 after treatment decrease, Week 8 after treatment decrease)
- Mean score of Positive and Negative Affect Schedule (PANAS)(Week 2 after treatment decrease, Week 8 after treatment decrease)
- weight evolution(Day 1, Week 2 after treatment decrease, Week 8 after treatment decrease)
- Proportion of patient with a SARS-CoV-2 viral load detection(Day 7 or the day of discharge from hospital if before day 7)
- Mean evolution of blood count(At randomization then every 3 days until discharge, or up to 5 weeks)
- Mean evolution of serum creatinine(At randomization then every 3 days until discharge, or up to 5 weeks)
- Mean evolution of C reactive protein(At randomization then every 3 days until discharge, or up to 5 weeks)
- Mean score of Cigarette Withdrawal Scale (CWS)(Week 2 after treatment decrease, Week 8 after treatment decrease)
- Survival rate(Day 14, Day 28)
- Proportion of transfer to intensive care unit (ICU)(Day 14, Day 28)
- Proportion of indication of transfer to intensive care unit (carried out or not in case of LATA)(Day 14, Day 28)
- Number of days living without non-invasive ventilation and mechanical ventilation(Day 4, Day 14, Day 28)
- Mean evolution of blood ionogram(At randomization then every 3 days until discharge, or up to 5 weeks)
- Mean score of Hospital anxiety and depression scale (HAD)(Week 2 after treatment decrease, Week 8 after treatment decrease)
- Mean score of Insomnia severity scale (ISI)(Week 2 after treatment decrease, Week 8 after treatment decrease)
- Number of days living without mechanical ventilation(Day 14, Day 28)
- Mean evolution of platelets(At randomization then every 3 days until discharge, or up to 5 weeks)
- Mean evolution of SaO2(At randomization then every 3 days until discharge, or up to 5 weeks)
- Proportion of active smoker or active vapers or taking nicotine substitutes documented by examination(Week 2 after treatment decrease, Week 8 after treatment decrease)
- Duration of hospitalization(Fom day 1 up to 3 month)
- Proportion of patient in each category of the World Health Organization 10-point Clinical Progression Scale(Day 7, Day 14 and Day 28)
- Proportion of patient in each category of the National Early Warning Scale (NEWS) 2(Day 7, Day14 and Day28 (or the day of discharge from hospital))
- Mean evolution of Interleukin 6 (IL-6)(At randomization then every 3 days until discharge, or up to 5 weeks)
- Mean evolution of oxygen requirements (number of liters / min)(At randomization then every 3 days until discharge, or up to 5 weeks)
- Proportion of active smoker or active vapers or taking nicotine substitutes documented by urinary cotinine(Week 8 after treatment decrease)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
Efficacy of Nicotine in Preventing COVID-19 InfectionCovid19SARS-Associated Coronavirus as Cause of Disease Classified ElsewhereNCT04583410Assistance Publique - Hôpitaux de Paris1,633
已完成
3 期
Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit PatientsCovid19SARS-Associated Coronavirus as Cause of Disease Classified ElsewhereNCT04598594Assistance Publique - Hôpitaux de Paris220
Unknown
4 期
Effect of Daily Nicotine Patch Application on Mechanical Ventilation Weaning in Smoking PatientsSmokingMechanical VentilationIntensive CareNCT01104896University of Paris 5 - Rene Descartes600
Unknown
4 期
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary SyndromeSmokingAcute Coronary SyndromeNCT01170338Newark Beth Israel Medical Center100
已完成
2 期
The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion ProductsNicotine Dependence, CigarettesNCT03492463Duke University94